-+ 0.00%
-+ 0.00%
-+ 0.00%

CORVUS PHARMACEUTICALS, - PRIMARY ENDPOINT IS SAFETY AND TOLERABILITY; KEY EFFICACY ENDPOINT IS HISCR 50/75 AT WEEK 12

路透·09/30/2026 20:05:00

请登录查看新闻详情